Bernstein Reaffirms Buy Rating for RELX PLC
Bernstein reaffirmed its Buy rating for RELX PLC, citing the potential for AI shopping agents to act as a tailwind for the company's risk insurance unit.
Stocks · News reference
Elsevier, a RELX company, has updated its ClinicalKey AI tool to integrate directly with patient medical records within Electronic Health Records (EHR) to support clinical decision-making.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bernstein reaffirmed its Buy rating for RELX PLC, citing the potential for AI shopping agents to act as a tailwind for the company's risk insurance unit.
Elsevier, a subsidiary of RELX, published a study indicating that 83% of academic librarians view artificial intelligence as a primary driver of change in research, while 81% express concerns regarding its potential misuse.
RELX PLC has reported a transaction in its own shares, a routine regulatory disclosure.
Elsevier, a division of RELX, published a global report surveying over 1,000 R&D leaders on the challenges of data-driven decision-making and the integration of AI in research and development.
LexisNexis Risk Solutions, a division of RELX, has introduced a new intelligence tool designed to help government agencies identify and manage risks associated with AI agents.
RELX PLC has filed for a block admission of 60,000 ordinary shares.